Company Profile
BioCardia Stock Price, News & Analysis
- Ticker:
- BCDA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.95 USD (-0.04%)
Close
Last updated: August 6, 2026
10.2M USD
Market cap
Why the stock is moving
Following the latest company update, “BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026”, BCDA closed up 4.37% at $0.9500 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Cardiovascular Cell Therapy Company
BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies.
CardiAMP Heart Failure Program
CardiAMP Cell Therapy is primarily being developed for ischemic heart failure with reduced ejection fraction. BioCardia has engaged both Japan’s PMDA and the FDA regarding safety, efficacy evidence, and potential approval pathways.
Delivery Platform Value
In addition to its own cell therapies, BioCardia serves as a biotherapeutic delivery partner for programs in heart failure, chronic myocardial ischemia, and acute myocardial infarction. The delivery technologies are an important component of the company’s platform value.
Dual-Market Regulatory Strategy
BioCardia is pursuing distinct approval paths in Japan and the United States. The Japanese Shonin process and the FDA-supported confirmatory study strategy provide separate routes for validating and commercializing the CardiAMP system.
Future catalysts
BioCardia is advancing a Japanese Shonin submission for the CardiAMP Cell Therapy System.
The FDA recommended continuation of the CardiAMP HF II trial as a confirmatory study supporting a potential PMA, making future enrollment and data key U.S. regulatory milestones.
Further FDA interaction regarding the Helix Transendocardial Delivery Catheter and a potential De Novo pathway could establish an additional regulatory milestone for the device platform.
Recent news
- 01
- 02
- 03
BioCardia Announces $4.4 Million Financing
Source: BioCardia
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioCardia (BCDA)?
BioCardia (BCDA) most recently closed at 0.95 USD, a -0.04% move versus the previous session.
What is the market cap of BioCardia (BCDA)?
BioCardia currently has a market capitalization of 10.2M USD on BioPharmSignal.
What does BioCardia do?
Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies. CardiAMP Heart Failure Program CardiAMP Cell Therapy is primarily...
On which exchange is BCDA stock listed?
BioCardia (BCDA) is associated with NASDAQ, United States, Biopharma.
What is Cardiovascular?
Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases.
Which conditions is BioCardia targeting with Cardiovascular?
BioCardia is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does BioCardia describe recent progress with Cardiovascular?
BioCardia is advancing a Japanese Shonin submission for the CardiAMP Cell Therapy System. The FDA recommended continuation of the CardiAMP HF II trial as a confirmatory study supporting a potential PMA, making future enrollment and data key U.S. regulatory milestones. Further FDA interaction regarding the Helix Transendocardial Delivery Catheter and a...
What is Cell?
Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases.